GPBAR1 and atherosclerosis: Interestingly, while the former studies suggested that the targeting of metabolite receptors could be used to regulate vascular inflammation and prevent atherosclerosis, the ablation of GPR109A and TGR5 signalling alone, in the absence of concomitant treatment with an excess of specific agonists, did not result in the acceleration of disease [55,56].